{"schema_version":"secwatch.filing_event.v1","accession":"0001576885-23-000056","form_type":"8-K","ticker":"ABOS","cik":"0001576885","company_name":"Acumen Pharmaceuticals, Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.605445+00:00","generated_at":"2026-06-08T06:41:42.261292+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Acumen licenses Halozyme ENHANZE tech for subcutaneous ACU193; seven-figure upfront","bullets":["Upfront payment in the seven-figure range for non-exclusive license to Halozyme's ENHANZE drug delivery technology.","Milestone payments tied to development/commercialization and net sales levels; single-digit royalties on worldwide net sales.","Halozyme named exclusive supplier of API for PH20 product for clinical and commercial supplies.","Agreement covers development of a subcutaneous formulation of ACU193."],"urls":{"canonical":"https://secwatch.observer/filing/0001576885-23-000056","json":"https://secwatch.observer/filing/0001576885-23-000056.json","markdown":"https://secwatch.observer/filing/0001576885-23-000056.md","text":"https://secwatch.observer/filing/0001576885-23-000056.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1576885/000157688523000056/0001576885-23-000056-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1576885/000157688523000056/abos-20231105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T06:41:42.261292+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"772be59ec7cb726bc96de1f925ac7ee793ec6c3c","claim":"Acumen Pharmaceuticals, Inc. entered into Non-exclusive Collaboration and License Agreement with Halozyme, Inc. valued at seven figure upfront payment (effective 2023-11-05).","evidence_excerpt":"On November 5, 2023, Acumen Pharmaceuticals, Inc. (the “ Company ”) entered into a Non-exclusive Collaboration and License Agreement (the “ Agreement ”) with Halozyme, Inc. (“ Halozyme ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1576885/000157688523000056/0001576885-23-000056-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Halozyme, Inc."},{"label":"Value","value":"seven figure upfront payment"},{"label":"Effective","value":"2023-11-05"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}